Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Matsumoto, Shuhei ^a   Cho, Sungsam ^a   Tosaka, Shinya ^b   Higashijima, Ushio ^a   Maekawa, Takuji ^a   Hara, Tetsuya ^a   Sumikawa, Koji ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Hyperglycemia; Levosimendan; Milrinone; Mitochondrial permeability transition pore; Myocardial infarction; Postconditioning

Indexed keywords

ATRACTYLOSIDE; LEVOSIMENDAN; MILRINONE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; CARRIER PROTEIN; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG DOSE INCREASE; GLUCOSE BLOOD LEVEL; HEART; HEART INFARCTION; HEART PROTECTION; HEART RATE; HYPERGLYCEMIA; MEAN ARTERIAL PRESSURE; NONHUMAN; POSTCONDITIONING; RAT; REPERFUSION; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HEART MUSCLE; HEMODYNAMICS; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REPERFUSION INJURY; TIME; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HYDRAZONES; HYPERGLYCEMIA; MALE; MILRINONE; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PYRIDAZINES; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84855615232     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-4     Document Type: Article

References (37)

1. Goyal A, Mehta SR, Díaz R, Gerstein HC, Afzal R, Xavier D, Liu L, Pais P, Yusuf S. Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation 2009, 120:2429-37. 10.1161/CIRCULATIONAHA.108.837765, 19948980.
2. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol 1998, 275:H721-5.
3. Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, Kersten JR. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 2002, 96:183-8. 10.1097/00000542-200201000-00032, 11753019.
4. Raphael J, Gozal Y, Navot N, Zuo Z. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol 2010, 55:348-57. 10.1097/FJC.0b013e3181d26583, 20125034.
5. Huhn R, Heinen A, Weber NC, Hollmann MW, Schlack W, Preckel B. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br J Anaesth 2008, 100:465-71. 10.1093/bja/aen022, 18305078.
6. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 2011, 14:781-90. 10.1089/ars.2010.3343, 20578962.
7. Niemann JT, Garner D, Khaleeli E, Lewis RJ. Milrinone facilitates resuscitation from cardiac arrest and attenuates postresuscitation myocardial dysfunction. Circulation 2003, 108:3031-5. 10.1161/01.CIR.0000101925.37174.85, 14638547.
8. Huang L, Weil MH, Tang W, Sun S, Wang J. Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med 2005, 33:487-91. 10.1097/01.CCM.0000156241.55872.15, 15753736.
9. Jebeli M, Ghazinoor M, Mandegar MH, Rasouli MR, Eghtesadi-Araghi P, Goodarzynejad H, Mohammadzadeh R, Darehzereshki A, Dianat S. Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: A randomized controlled trial. Cardiol J 2010, 17:73-8.
10. Eriksson HI, Jalonen JR, Heikkinen LO, Kivikko M, Laine M, Leino KA, Kuitunen AH, Kuttila KT, Peräkylä TK, Sarapohja T, Suojaranta-Ylinen RT, Valtonen M, Salmenperä MT. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg 2009, 87:448-54. 10.1016/j.athoracsur.2008.10.029, 19161758.
11. Yano M, Kohno M, Ohkusa T, Mochizuki M, Yamada J, Kohno M, Hisaoka T, Ono K, Tanigawa T, Kobayashi S, Matsuzaki M. Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 2000, 279:H1898-905.
12. Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995, 26:S45-51.
13. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000, 90:5-11. 10.1097/00000539-200001000-00003, 10624967.
14. du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 2008, 154:41-50. 10.1038/bjp.2008.52, 2438987, 18297097.
15. Hönisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol 2010, 105:155-67. 10.1007/s00395-009-0064-9, 19842009.
16. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, Asakura M, Ogita H, Liao Y, Sakata Y, Ogai A, Fukushima T, Yamada J, Shinozaki Y, Kuzuya T, Mori H, Terada N, Hori M. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 2001, 104:705-10. 10.1161/hc3201.092216, 11489779.
17. Matsumoto S, Cho S, Tosaka S, Ureshino H, Maekawa T, Hara T, Sumikawa K. Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway. Cardiovasc Drugs Ther 2009, 23:263-70. 10.1007/s10557-009-6184-5, 19597978.
18. Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint R. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol Scand 2009, 53:941-8. 10.1111/j.1399-6576.2009.01994.x, 19426242.
19. Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, Warltier DC. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 2001, 280:H1744-50.
20. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005, 54:2360-4. 10.2337/diabetes.54.8.2360, 16046302.
21. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009, 104:189-202. 10.1007/s00395-009-0010-x, 19242644.
22. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 2006, 281:20801-8. 10.1074/jbc.M600959200, 16720572.
23. Tosaka S, Makita T, Tosaka R, Maekawa T, Cho S, Hara T, Ureshino H, Sumikawa K. Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. J Anesth 2007, 21:176-80. 10.1007/s00540-006-0485-7, 17458647.
24. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008, 108:243-50. 10.1097/01.anes.0000299437.93898.4a, 18212569.
25. Tanaka K, Weihrauch D, Ludwig L, M Kersten JR, Pagel PS, Warltier DC. Mitochondrial adenosine triphosphate-regulated potassium channel opening acts as a trigger for isoflurane-induced preconditioning by generating reactive oxygen species. Anetshesiology 2003, 98:935-43.
26. Kehl F, Krolikowski JG, Weihrauch D, Pagel PS, Warltier DC, Kersten JR. N-acetylcysteine restores isoflurane-induced preconditioning against myocardial infarction during hyperglycemia. Anetshesiology 2003, 98:1384-90.
27. Ku PM, Chen LJ, Liang JR, Cheng KC, Li YX, Cheng JT. Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractility. Cardiovasc Diabetol 2011, 10:57. 10.1186/1475-2840-10-57, 3141394, 21702924.
28. Kageyama S, Yokoo H, Tomita K, Kageyama-Yahara N, Uchimido R, Matsuda N, Yamamoto S, Hattori Y. High glucose-induced apoptosis in human coronary artery endothelial cells involves up-regulation of death receptors. Cardiovasc Diabetol 2011, 10:73. 10.1186/1475-2840-10-73, 3161855, 21816064.
29. Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, Tourmen Y, Henrion D, Furber A, Prunier F. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol 2010, 106:147-62.
30. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 2007, 56:127-36. 10.2337/db06-0907, 17192474.
31. Higashijima U, Cho S, Matsumoto S, Ureshino H, Sumikawa K. The Role of Protein Kinase C in Milrinone- and Levosimendan-Induced Postconditioning in Rat Hearts. In Proceedings of the 2010 Annual Meeting of the American Society of Anesthesiologists, October 16-20, 2010; San Diego, California.
32. Higashijima U, Cho S, Ureshino H, Matsumoto S, Sumikawa K. Differential Mechanisms of Milrinone- and Levosimendan-Induced Postconditioning in Rat Hearts. In Proceedings of the 2009 Annual Meeting of the American Society of Anesthesiologists, October 17 - 21, 2009; New Orleans, Louisiana.
33. Caimmi PP, Molinari C, Uberti F, Micalizzi E, Valente G, Mary DA, Vacca G, Grossini E. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg 2011, 39:e59-67. 10.1016/j.ejcts.2010.11.044, 21247774.
34. Huang MH, Wu Y, Nguyen V, Rastogi S, McConnell BK, Wijaya C, Uretsky BF, Poh KK, Tan HC, Fujise K. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther 2011, 25:223-32. 10.1007/s10557-011-6302-z, 3110274, 21562974.
35. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006, 38:414-9. 10.1016/j.biocel.2005.09.017, 16280253.
36. Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CM. CLARITY-TIMI 28 Investigators: Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol 2008, 101:303-7. 10.1016/j.amjcard.2007.08.034, 18237589.
37. Gu W, Pagel PS, Warltier DC, Kersten JR. Modifying cardiovascular risk in diabetes mellitus. Anesthesiology 2003, 3:774-9.